Services Tecfidera Medicine Exporters

Tecfidera Medicine Exporters

Derek Clarke is a leading UK-based Tecfidera medicine exporter.


Tecfidera (dimethyl fumarate, Biogen Idec) is an oral treatment approved for the treatment of relapsing forms of multiple sclerosis (MS), the most common form of MS.


In two phase 3 clinical trials, Tecfidera was shown to significantly reduce relapse rates and disability progression compared to both placebo and the comparator Copaxone (glatiramer acetate).


In the first trial, DEFINE, Tecfidera was shown to reduce relapse rates by between 48% and 53%, and disability progression by between 34% and 38% compared to placebo.


The second trial, CONFIRM, showed that Tecfidera reduced relapse rates by between 44% and 51%, compared to a 29% reduction in those taking Copaxone. It also reduced disability progression by between 21% and 24%, compared to 7% for Copaxone.


MRI scans in both trials also showed a significant reduction in new or newly enlarging brain lesions, the damage caused by MS, after two years in those treated with Tecfidera compared with those treated with either placebo or Copaxone.


It is important to note that Tecfidera can cause side-effects and these should be discussed with healthcare professionals.


Derek Clarke, with more than 30 years as experience as an exporter of both branded and generics drugs, is able to source and supply products, often unavailable through other sources, quickly and efficiently.  


For more information on our Tecfidera medicine exports, please contact us on


+44 (0) 208 952 2061